Tempus AI, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Eric Lefkofsky
- Full Time Employees
- 3,800
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 600 West Chicago Avenue Chicago IL United States of America 60654
- IPO Date
- Jun 14, 2024
- CIK
- 0001717115
- Website
- tempus.com
- Similar Companies
- Business
- Tempus AI, Inc. operates as an innovative healthcare technology firm, dedicated to transforming patient care through the application of artificial intelligence. The company specializes in delivering comprehensive genomic sequencing diagnostics, including next-generation sequencing, polymerase chain reaction profiling, and advanced molecular pathology testing to a broad spectrum of healthcare entities. These clients include medical providers, pharmaceutical manufacturers, biotechnology innovators, and research institutions. The organization provides a suite of advanced platforms such as Tempus Lens, designed for scientists to explore, access, and analyze de-identified clinical, molecular, and imaging data, and Tempus Hub, a streamlined desktop and mobile interface for managing test orders and patient results. Their offerings also encompass predictive algorithmic tests, like Algos and Next, tailored for oncology and other therapeutic areas, as well as Trials, a service that facilitates patient matching for clinical studies. Tempus AI generates revenue primarily through its genomic testing services, data licensing, and clinical trial solutions. The company notably expanded its reach by going public on Nasdaq in June 2024 under the ticker TEM. Recent strategic developments include the November 2024 acquisition of Ambry Genetics, a $600 million deal, and the formation of SB Tempus, an AI healthcare joint venture in Japan with SoftBank. In April 2025, Tempus AI, AstraZeneca, and Pathos AI announced multi-year agreements, including $200 million in data licensing and model development fees to Tempus, to co-develop a significant multimodal foundation model in oncology, building on an earlier 2021 partnership. Further collaborations in 2025 include a partnership with Illumina for genomic testing integration and research alliances with Northwestern University for Alzheimer's disease and the Institute for Follicular Lymphoma Innovation. Headquartered in Chicago, Illinois, Tempus AI was established in 2015 and remains at the forefront of leveraging large-scale multimodal data and AI to accelerate precision medicine, with a significant presence among U.S. oncologists and top biopharma companies.
Company News
10 Stocks With Massive Short Squeeze Potential
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
The Top HealthTech Questions Landing on Our Desks
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus AI (NASDAQ:TEM) Stock: Insider Eric Lefkofsky Sells 250,000 Shares
Top Performing Leveraged/Inverse ETFs: 09/20/2026
Tempus AI Chief Accounting Officer Sells $529,650 of Stock
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement
3 Analysts, 3 Trades to Make Today
Tempus AI: High Risk, But With A Great Cause
Tempus AI: Data And Applications Will Unlock More Upside
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model
Ryan Fukushima Sells 700 Shares of Tempus AI (NASDAQ:TEM) Stock
Ryan Bartolucci Sells 7,062 Shares of Tempus AI (NASDAQ:TEM) Stock
Andrew Polovin Sells 2,951 Shares of Tempus AI (NASDAQ:TEM) Stock
Tempus AI stock is soaring: does it have more upside to go?
Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength?
Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook